SDZ ASM 981

BioDrugs

Volumn 14, Issue 6, 2000, Pages 409-416

  Wellington, Keri ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CLOBETASOL; CORTICOSTEROID; DIFLUCORTOLONE; FLUPREDNIDENE; FLUTICASONE PROPIONATE; LACTAM DERIVATIVE; MOMETASONE FUROATE; PIMECROLIMUS;

ADULT; ATOPIC DERMATITIS; ATROPHY; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN ALLERGY;

EID: 0034495133     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014060-00005     Document Type: Review

References (9)

1. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999 Aug; 141: 264-73
2. Hultsch T, Müller KD, Meingassner JG, et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998 Sep; 290: 501-7
3. Howarth PH. Pathogenic mechanisms: a rational basis for treatment. BMJ 1998 Mar 7; 316: 758-61
4. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th I subset. J Invest Dermatol 1994 Feb; 102 (2): 145-9
5. Friedmann PS. Allergy and the skin. II. Contact and atopic eczema. BMJ 1998 Apr 18; 316: 1226-9
6. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drug 2000 Jan; 9: 69-77
7. Landow K. Atopic dermatitis: current concepts support old therapies and spur new ones. Postgrad Med 1997 Mar; 101 (3): 101-4
8. Zuberbier T, Chong S, Guhl S, et al. SDZ ASM 981 inhibits anti-IgE stimulated mediator release in human dermal mast cells [abstract]. J Invest Dermatol 1999 Apr; 112: 608
9. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997 Oct; 137: 568-76